LYell SYndrome MEsenchymal Stromal Cells Treatment

Recruiting Phase 1 Phase 2 Interventional Study
Epidermal Necrolysis Lyell Syndrome Toxic Epidermal Necrolysis Overlap Syndrome Mesenchymal Stromal Cells Adipose Derived Stromal Cells
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 75
Sex
Any
Trial phase
Phase 1/2
Study type
Interventional
Purpose
Treatment
Participants needed
15 (estimated)
Sponsor
Assistance Publique - Hôpitaux de Paris · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare severe cutaneous adverse reactions (SCARs) to drugs. To date, no curative drug has demonstrated with a good level of evidence its ability to promote SJS and TEN healing and could contribute to earlier reepithelialisation. Mesenchymal stroma cells (MSCs) therapy represents a new therapeutic approach. eg, in patients with …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients ≥ 18 and ≤ 75 years-old * Admission ≤ 10 days after the index date (date of the first symptoms of the disease) * Patient with confirmed SJS-TEN diagnosis hospitalized in the department of Dermatology or intensive care medicine * At least 10 % of detachable-detached bo…
Contacts

Saskia Oro, MD

0149812536

saskia.oro@aphp.fr

CONTACT

Charline Menanteau, MSc

0144841752

myriem.carrier@aphp.fr

CONTACT